The King's Brief Lnterstitial Lung Disease Questionnaire

July 7, 2026 updated by: Elif Gur Kabul, Pamukkale University

Investigation of the Turkish Validity and Reliability of The King's Brief Interstitial Lung Disease Questionnaire (K-BILD) in Individuals With Interstitial Lung Involvement Secondary to Rheumatological Diseases

The aim of this study is to examine the validity and reliability of the Turkish Validity and Reliability of The King's Brief Interstitial Lung Disease Questionnaire (K-BILD) in Individuals with Interstitial Lung Involvement Secondary to Rheumatological Diseases.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

45

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

All patient-reported outcome measurements will be administered once, and King's Brief Interstitial Lung Disease Questionnaire will be administered twice, one week apart.

Description

Inclusion Criteria:-Having been diagnosed with interstitial lung disease by a rheumatologist,

  • Being 18 years of age or older,
  • Agreeing to participate in the study.

Exclusion Criteria:- Presence of a neurological disease

  • Presence of any orthopedic problem that affects functionality
  • History of any orthopedic surgery in the last year
  • Inability to speak or understand Turkish fluently
  • Presence of a psychiatric illness that affects cooperation
  • Heart failure that affects daily living activities
  • Being a cancer patient

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group I
Interstitial Lung Involvement Secondary to Rheumatological Diseases
Behavioral: patient reported outcome measures
King's Brief lnterstitial Lung Disease Questionnaire, Arthritis Impact Measurement Scales (AIMS2)-Short Form, Modified Medical Research Council (mMRC) Dyspnea Scale, Visual Analog Scale were evaluated.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
King's Brief lnterstitial Lung Disease Questionnaire
Time Frame: 10 minutes
It consists of 15 items and has a seven-point Likert scale.
10 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Arthritis Impact Measurement Scales (AIMS2)-Short Form
Time Frame: 15 minutes
AIMS2-SF is a 26-item shortened form of AIMS2 and covers five components of quality of life.
15 minutes
Modified Medical Research Council (mMRC) Dyspnea Scale
Time Frame: 5 minutes
This scale provides information about perceived levels of shortness of breath, consisting of five stages.
5 minutes
Visual Analog Scale
Time Frame: 3 minutes
In our study, "respiratory distress" will be assessed using the Visual Analog Scale. 0 will be defined as "I never experience respiratory distress," and 10 as "I do not always experience respiratory distress."
3 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Pamukkale University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 5, 2026

Primary Completion (Estimated)

January 15, 2027

Study Completion (Estimated)

May 15, 2027

Study Registration Dates

First Submitted

July 7, 2026

First Submitted That Met QC Criteria

July 7, 2026

First Posted (Actual)

July 13, 2026

Study Record Updates

Last Update Posted (Actual)

July 13, 2026

Last Update Submitted That Met QC Criteria

July 7, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Turkish Validity Reliability

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Interstitial Lung Disease Due to Systemic Disease

Clinical Trials on patient reported outcome measures

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe